Your browser doesn't support javascript.
loading
Differential diagnosis of necrotizing myopathy.
Selva-O'Callaghan, Albert; Trallero-Araguás, Ernesto; Milisenda, Jose C; Grau-Junyent, Josep M.
Afiliación
  • Selva-O'Callaghan A; Systemic Autoimmune Diseases Unit, Vall d'Hebron Hospital, Internal Medicine Department, University Autonomous of Barcelona.
  • Trallero-Araguás E; Rheumatology Department, Vall d'Hebron Hospital.
  • Milisenda JC; Internal Medicine Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.
  • Grau-Junyent JM; Internal Medicine Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.
Curr Opin Rheumatol ; 33(6): 544-553, 2021 11 01.
Article en En | MEDLINE | ID: mdl-34482348
ABSTRACT
PURPOSE OF REVIEW Necrotizing myopathy is a broad term. It includes patients with the recently described immune-mediated necrotizing myopathies (IMNM) who have specific antibodies, such as anti-hydroxy-3-methylglutaryl-CoA reductase or anti-signal recognition particle, seronegative phenotypes that can be associated with cancer, and other types of myositis and connective tissue diseases involving necrotic muscle fibers as a characteristic pathologic feature. Necrotizing myopathies that are not immune-mediated, such as those caused by drugs, dystrophies, infections, or even hypothyroidism are also included. The purpose of this review is to address the differential diagnosis of these disorders. RECENT

FINDINGS:

New IMNM have been described over the last few years, some of them related with checkpoint inhibitors, drugs that are being increasingly used in cancer treatment. Necrotizing myopathy has also been reported in association with specific phenotypes and autoantibodies (e.g. anti-Mi2 dermatomyositis, antisynthetase syndrome, and myositis associated with antimitochondrial antibodies). Rarer cases associated with graft-versus-host disease and severe acute respiratory syndrome coronavirus 2 infection are also emerging.

SUMMARY:

Differentiation between patients with IMNM and those without the superimposed autoimmune phenomena helps clinicians determine the best individualized approach to use and the appropriate immunosuppressive therapy, whenever needed.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / COVID-19 / Enfermedades Musculares / Miositis Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Curr Opin Rheumatol Asunto de la revista: REUMATOLOGIA Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / COVID-19 / Enfermedades Musculares / Miositis Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Curr Opin Rheumatol Asunto de la revista: REUMATOLOGIA Año: 2021 Tipo del documento: Article